Mild Cognitive Impairment
Conditions
Interventions
The acupuncture group based on the concept of"Olfactory-Brain Co-treatment":Acupuncture at the following points:Baihui(GV20)Shenting(GV24)Sishencong(EX-HN1)Yintang(EX-HN3)Yingxiang(LI20)Sanyinjiao(SP6
The non-meridian and non-acupoint acupuncture group:Acupuncture at non-meridian and non-acupoint locations adjacent to Baihui(GV20),Shenting(GV24),Sishencong(EX-HN1),Yintang(EX-HN3),Yingxiang(LI20),Sa
Sponsors
General Hospital of the Western Theater Command of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
55 Years to 80 Years
Inclusion criteria
Inclusion criteria: Participants who meet all of the following seven criteria are eligible for inclusion in this study: (1)Meet the diagnostic criteria for MCI(Mild Cognitive Impairment); (2)Have a disease duration of=3 months; (3)Are aged between 55 and 80 years old; (4)Have no significant speechvisualor hearing impairments and are able to complete neuropsychological assessments and related evaluations; (5)Have olfactory dysfunction as indicated by the CSIT(Cross-Cultural Smell Identification Test)results; (6)Possess sufficient comprehension ability to make independent judgments and fully understand the purposecontentand related procedures of the study; (7)Voluntarily agree to participate in this studyare able to comply with the study protocoland have signed the informed consent form.
Exclusion criteria
Exclusion criteria: Participants meeting any of the following criteria will be excluded: (1) Diagnosed with dementia or currently taking cognitive-enhancing medications; (2) Cognitive impairment caused by other conditions such as acute cerebrovascular disease central nervous system infections intracranial space-occupying lesions Parkinsons disease traumatic brain injury thyroid and parathyroid disorders diabetes poisoning epilepsy syphilis psychiatric disorders or severe vitamin deficiencies; (3) History of nasal fractures or nasal surgery or presence of olfactory dysfunction-related conditions (e.g. chronic rhinitis allergic rhinitis nasal polyps) or upper respiratory tract infection within the past two weeks; (4) Long-term or heavy exposure to volatile substances such as pesticides herbicides metal dust acid fumes industrial solvents cleaning products or sawdust; (5) History of drug abuse or heavy alcoholism within the past two years or long-term use of medications that affect cognitive function (e.g. corticosteroids antipsychotics sedative-hypnotics); (6) Pseudo-cognitive impairment due to mood disorders (e.g. moderate to severe depression) with a Hamilton Depression Scale (HAMD) score =18; (7) Intellectual disability or neurodevelopmental delay; (8) Current participation in other clinical trials involving cognitive interventions; (9) Subjects with impaired comprehension who are unable to make independent judgments or decisions and fail to fully understand the trial objectives content and related procedures; (10)Liver function indicators(ALT or AST)exceeding 1.5 times the upper limit of normalrenal function(Cr)exceeding 1.5 times the upper limit of the normal rangemoderate or severe anemiaor having life-threatening acute or serious somatic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment(MoCA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale(HAMD);Mini-Mental State Examination(MMSE);Activities of Daily Living(ADL);the Chinese Smell Identification Test(CSIT);Clinical Dementia Rating(CDR); | — |
Countries
China
Contacts
Public ContactPang Rizhao
General Hospital of the Western Theater Command of the Chinese People's Liberation Army
Outcome results
None listed